Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RKDA
RKDA logo

RKDA Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
0.727
Open
0.690
VWAP
0.71
Vol
156.10K
Mkt Cap
4.10M
Low
0.668
Amount
110.06K
EV/EBITDA(TTM)
--
Total Shares
5.94M
EV
-2.30M
EV/OCF(TTM)
--
P/S(TTM)
0.22
Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.
Show More

Events Timeline

(ET)
2026-06-26
17:00:00
Arcadia Biosciences Files to Sell 11.92M Shares of Common Stock
select
2026-06-11 (ET)
2026-06-11
21:00:00
Arcadia Biosciences Sells 3,883,496 Shares at $1.03 Each
select
2026-01-28 (ET)
2026-01-28
06:10:00
Arcadia Biosciences Files to Sell 1.67M Shares of Common Stock
select
2026-01-20 (ET)
2026-01-20
06:10:00
Rockwell Medical Sees Q4 Gross Margin Rise to 22%
select
2026-01-12 (ET)
2026-01-12
08:50:00
Arcadia Biosciences Issues Preferred Investment Options, Raises Approximately $2.1M
select
2026-01-05 (ET)
2026-01-05
06:10:00
Rockwell Medical Extends Agreement with Major US Dialysis Provider to December 31, 2026
select
2025-12-26 (ET)
2025-12-26
16:10:00
Stocks Fluctuate Near All-Time Highs, S&P 500 Slightly Declines
select
2025-12-26
08:10:00
Arcadia CEO Announces Evaluation of Strategic Alternatives to Create Shareholder Value
select
2025-12-26
08:10:00
Arcadia Biosciences Terminates Securities Exchange Agreement with Roosevelt Resources
select
2025-12-15 (ET)
2025-12-15
07:00:00
Rekor Systems Prices 8,571,428 Units Direct Offering at $1.75 Each
select

News

Newsfilter
8.5
06-13Newsfilter
Arcadia Biosciences Closes Private Placement Raising $4 Million
  • Financing Size: Arcadia Biosciences has successfully completed a private placement of 3,883,496 shares of common stock, raising approximately $4 million, indicating the company's active engagement in capital markets and its financing capabilities.
  • Investment Options Details: The financing includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately exercisable, enhancing investor flexibility.
  • Use of Proceeds: The company intends to utilize the proceeds for working capital and general corporate purposes, which will support the development and marketing of its innovative products, further solidifying its competitive position in the wellness product sector.
  • Compliance Statement: The securities offered were conducted under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious approach to compliance and ensuring future capital operations adhere to relevant laws and regulations.
seekingalpha
8.5
06-12seekingalpha
Arcadia Biosciences Announces Private Placement of Common Stock
  • Private Placement Agreement: Arcadia Biosciences (RKDA) has entered into securities purchase agreements for a private placement of approximately 3.88 million shares of common stock at a price of $1.03 per share, aiming to raise about $4 million in gross proceeds, indicating the company's ability to access capital markets.
  • Clear Use of Proceeds: The net proceeds from this offering will be allocated for working capital and general corporate purposes, highlighting the company's focus on liquidity in the current market environment, which is intended to enhance its operational capacity and competitive position.
  • Transaction Timeline: The offering is expected to close on or about June 12, demonstrating the company's efficiency in responding to market demands and capital raising, which will help maintain flexibility in future business development.
  • Stock Price Impact: Following the announcement of the financing, RKDA's stock traded about 8% lower during pre-market hours on Friday, reflecting market caution regarding the financing plan and potentially affecting investor confidence in the company's future performance.
NASDAQ.COM
8.5
06-12NASDAQ.COM
Arcadia Biosciences Announces Stock Offering
  • Stock Offering Announcement: Arcadia Biosciences has entered into agreements to sell 3.88 million shares of common stock and Series A-1 and A-2 preferred investment options, with expected gross proceeds of approximately $4 million, indicating a proactive approach to financing.
  • Clear Use of Proceeds: The net proceeds from this offering will be utilized for working capital and general corporate purposes, reflecting the company's strategic intent to expand operations and enhance financial flexibility.
  • Negative Market Reaction: Despite the offering price set at $1.03 per share, RKDA's stock fell by 3.74% in the latest trading session and further declined by 5.61% in after-hours trading, signaling investor concerns regarding the company's outlook.
  • Investor Attention on Expiration: The Series A-1 options expire five years after shareholder approval, while the Series A-2 options expire 24 months after the effectiveness of the resale registration statement, necessitating investor awareness of these timelines and their implications for future financing.
Newsfilter
8.5
06-12Newsfilter
Arcadia Biosciences Announces Private Placement of Common Stock
  • Financing Size: Arcadia Biosciences announced a private placement of 3,883,496 shares of common stock, with expected gross proceeds of approximately $4 million, which will be utilized for working capital and general corporate purposes, thereby enhancing the company's financial flexibility.
  • Preferred Investment Options: The offering includes Series A-1 and A-2 preferred investment options, both priced at an exercise price of $0.91 per share, with A-1 options exercisable upon shareholder approval and A-2 options immediately, indicating the company's proactive approach to future capital operations.
  • Market Compliance: The securities are offered under Section 4(a)(2) of the Securities Act of 1933, remaining unregistered in the U.S., reflecting the company's cautious stance on compliance while also limiting the liquidity of the securities, which may affect investor participation.
  • Future Outlook: The company plans to close the offering on June 12, 2026, subject to customary closing conditions, and if successful, this will provide essential funding support for its future operations and innovations, aiding its further development in the health products market.
seekingalpha
9.5
03-26seekingalpha
Arcadia Biosciences Reports Q4 Financial Results
  • Disappointing Financial Results: Arcadia Biosciences reported a Q4 GAAP EPS of -$0.97, indicating significant challenges in profitability and reflecting ongoing financial pressures on the company.
  • Significant Revenue Decline: The company’s Q4 revenue was $0.9 million, down 26.2% year-over-year, a trend that may undermine investor confidence in the company’s future growth potential, particularly in the competitive biotech sector.
  • Negative Market Reaction: The earnings report, which fell short of market expectations, could lead investors to adopt a cautious stance regarding the company’s future financial performance, potentially putting pressure on the stock price and affecting its ability to raise capital and pursue strategic investments.
  • Need for Strategic Reevaluation: In light of the ongoing revenue decline, Arcadia Biosciences may need to reassess its business model and market strategies to achieve sustainable growth in the future and restore investor confidence.
moomoo
7.5
03-26moomoo
Arcadia Biosciences Reports Q4 Operating Expenses of $2.276 Million
  • Operating Expenses: The operating expenses for Arcadia Biosciences in the fourth quarter amounted to USD 2.276 million.

  • Financial Overview: The report highlights the financial performance and expenditures of the company during the specified quarter.

  • Company Focus: Arcadia Biosciences is engaged in biotechnology, focusing on developing innovative agricultural solutions.

  • Future Outlook: The financial results may influence future investments and strategic decisions for the company moving forward.

Valuation Metrics

The current forward P/E ratio for Arcadia Biosciences Inc (RKDA.O) is 36.63, compared to its 5-year average forward P/E of 2.60. For a more detailed relative valuation and DCF analysis to assess Arcadia Biosciences Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
2.60
Current PE
36.63
Overvalued PE
15.06
Undervalued PE
-9.87

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.33
Current EV/EBITDA
-0.08
Overvalued EV/EBITDA
1.11
Undervalued EV/EBITDA
-0.45

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.06
Current PS
0.18
Overvalued PS
1.86
Undervalued PS
0.27

Financials

AI Analysis
Annual
Quarterly

Whales Holding RKDA

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Arcadia Biosciences Inc (RKDA) stock price today?

The current price of RKDA is 0.719 USD — it has increased 4.21

What is Arcadia Biosciences Inc (RKDA)'s business?

Arcadia Biosciences, Inc. is a producer and marketer of plant-based health and wellness products. The Company’s product portfolio includes Zola Coconut Water (Zola) and Agronomic Wheat Traits. Zola is a natural, 100% coconut water. Zola is a non-genetically modified organisms (non-GMO) project verified and only contains 60 calories per serving. Zola flavors include original, original with pulp, espresso, lime and pineapple. The recipe with Zola includes smoothies, desserts, cocktails and mocktails, and bowls. It has developed a portfolio of non-GMO specialty wheat traits to offer healthier, nutrient-rich wheat options while providing the same baking quality, taste, and texture as traditional wheat. Its non-GMO Reduced Gluten High Fiber Wheat has fewer allergenic glutens and higher fiber than traditional wheat, while its non-GMO Extended Shelf-Life Wheat extends the shelf life of milled whole wheat flour.

What is the price predicton of RKDA Stock?

Wall Street analysts forecast RKDA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RKDA is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Arcadia Biosciences Inc (RKDA)'s revenue for the last quarter?

Arcadia Biosciences Inc revenue for the last quarter amounts to 1.10M USD, decreased -8.33

What is Arcadia Biosciences Inc (RKDA)'s earnings per share (EPS) for the last quarter?

Arcadia Biosciences Inc. EPS for the last quarter amounts to -2.11 USD, decreased -211.05

How many employees does Arcadia Biosciences Inc (RKDA). have?

Arcadia Biosciences Inc (RKDA) has 8 emplpoyees as of June 30 2026.

What is Arcadia Biosciences Inc (RKDA) market cap?

Today RKDA has the market capitalization of 4.10M USD.